Iovance Biotherapeutics IOVA shares are surging on Tuesday following the announcement of positive early data from a pilot ...

Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE ...

The company announced encouraging early results from a pilot study evaluating its tumor-infiltrating lymphocyte therapy, ...

Iovance Biotherapeutics shares rose after the company shared positive trial results from a treatment designed for soft tissue cancer. The stock gained 26% to $3.65 Tuesday. Shares are still down 32% ...

Investing.com -- Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares jumped 32% Tuesday following positive early data from a pilot clinical trial of lifileucel in patients with advanced undifferentiated ...

Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.

Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to sell off its remaining assets. | BioAtla is laying off 70% of its workforce as the antibody biotech mulls whether to ...

Equity-Insider.com News Commentary -- The five-year cancer survival rate in the United States has reached a record 70%, reflecting decades of progress in early detection, targeted therapy, and ...

Quarterly Revenue Growth Driven by Amtagvi DemandGross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast ...

In an early-stage clinical trial, half the patients with advanced undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma responded to the TIL therapy.

I think you will see total product guidance; you will see some guidance potentially on quarters, we will have to see how our ...